Novavax, Cadila Pharmaceuticals deal

Novavax and Cadila formed CPL Biologics Ltd, a JV to develop and commercialize vaccines, pharmaceuticals and diagnostics in India. Cadila will own 80% of the JV and Novavax will own the remaining 20%.

The JV will have an exclusive, royalty-free license in India to develop and commercialize Novavax's seasonal influenza virus-like particle (VLP) vaccine and other VLP vaccine candidates against diseases of concern, like hepatitis E and chikungunya fever. Novavax's trivalent VLP vaccine against the H3N1, H1N1 and B strains of influenza virus is in Phase II testing. The JV also will have an option to license Novavax's H5N1 VLP pandemic influenza vaccine, which is in Phase I/IIa testing. Novavax will have rights to negotiate ex-Indian licenses for vaccines developed by the JV. ...